RATIONALE-302

NCT03430843 📎

Regimen

Experimental
tislelizumab
Control
investigator-choice chemotherapy (paclitaxel, docetaxel, or irinotecan)

Population

Advanced or metastatic ESCC after first-line progression

Key finding

All pts mOS 8.6 vs 6.3 mo (HR 0.70, 95% CI 0.57-0.85, p=0.0001); PD-L1 TAP>=10% mOS 10.3 vs 6.8 mo (HR 0.54); ORR 20.3% vs 9.8%; grade>=3 TRAE 18.8% vs 55.8%

Source: PMID 35442766

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.66)